Confronta i metodi

	Trial Clinico Bayesiano di Fase I	Analisi Dose-Risposta
Campo	Epidemiologia	Epidemiologia
Famiglia	Process / pipeline	Process / pipeline
Anno di origine	1990	Conceptual roots 16th century; modern epidemiological application mid-20th century
Ideatore	O'Quigley, Pepe & Fisher (Continual Reassessment Method)	Paracelsus (conceptual foundation); formalized by John Snow and later Bradford Hill
Tipo	Adaptive Bayesian dose-finding design	Quantitative analytical method
Fonte seminale	O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48.	Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641
Alias	Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study	exposure-response analysis, concentration-response modeling, dose-response modeling, DRA
Correlati	5	4
Sintesi	A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses.	Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference.